Literature DB >> 21565178

Association between SNPs in pre-miRNA and risk of chronic obstructive pulmonary disease.

Li-Juan Li1, Lin-Bo Gao, Mei-Li Lv, Wei Dong, Xiao-Wei Su, Wei-Bo Liang, Lin Zhang.   

Abstract

OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airway obstruction and persistent chronic airway inflammation and is influenced by genetic and environmental factors. This study aimed to explore the genetic aspect of its initial occurrence. DESIGN AND METHODS: We conducted a case-control study of 432 COPD patients and 511 control subjects frequency-matched in age and gender distribution. We genotyped three single nucleotide polymorphisms (SNPs) in pre-miRNAs using a PCR-RFLP assay and evaluated their relevance to COPD susceptibility.
RESULTS: We found that the TT genotype and T allele of miR-196a2 rs11614913 were significantly associated with a decreased risk for COPD, compared with the CC genotype and C allele. Similarly, the GG genotype and G allele of miR-499 rs3746444 were associated with a decreased risk for COPD, compared with the AA genotype and A allele.
CONCLUSIONS: These findings suggest that both rs11614913 and rs3746444 may be involved in susceptibility to COPD.
Copyright © 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565178     DOI: 10.1016/j.clinbiochem.2011.04.021

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  15 in total

1.  Association of the miR-196a2, miR-146a, and miR-499 Polymorphisms with Asthma Phenotypes in a Korean Population.

Authors:  Hoang Kim Tu Trinh; Duy Le Pham; Su-Chin Kim; Ri-Yeon Kim; Hae-Sim Park; Seung-Hyun Kim
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

Review 2.  Epigenetic targets for novel therapies of lung diseases.

Authors:  Brian S Comer; Mariam Ba; Cherie A Singer; William T Gerthoffer
Journal:  Pharmacol Ther       Date:  2014-11-15       Impact factor: 12.310

3.  The miR-196a SNP Rs11614913 but not the miR-499 rs37464444 SNP is a Risk Factor for Non-small Cell Lung Cancer in an Iranian Population.

Authors:  Neda K Dezfuli; Ian M Adcock; Shamila D Alipoor; Babak Salimi; Sharareh Seifi; Mohammad Chehrazi; Mohammad Varahram; Esmaeil Mortaz
Journal:  Tanaffos       Date:  2022-01

4.  MiR-196a2 rs11614913 T>C Polymorphism is Associated with an Increased Risk of Tetralogy of Fallot in a Chinese Population.

Authors:  Jian-Bing Huang; Ju Mei; Lian-Yong Jiang; Zhao-Lei Jiang; Hao Liu; Jun-Wen Zhang; Fang-Bao Ding
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

5.  Precursor miR-499a Variant but not miR-196a2 is Associated with Rheumatoid Arthritis Susceptibility in an Egyptian Population.

Authors:  Eman A Toraih; Nesreen M Ismail; Ahmed A Toraih; Mohammad H Hussein; Manal S Fawzy
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

Review 6.  Updates on the COPD gene list.

Authors:  Yohan Bossé
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-18

Review 7.  The pathogenesis of COPD and IPF: distinct horns of the same devil?

Authors:  Marco Chilosi; Venerino Poletti; Andrea Rossi
Journal:  Respir Res       Date:  2012-01-11

8.  Meta-analysis of Hsa-mir-499 polymorphism (rs3746444) for cancer risk: evidence from 31 case-control studies.

Authors:  Chen Chen; Shenglan Yang; Sandip Chaugai; Yan Wang; Dao Wen Wang
Journal:  BMC Med Genet       Date:  2014-11-30       Impact factor: 2.103

Review 9.  Novel insights into miRNA in lung and heart inflammatory diseases.

Authors:  Amit Kishore; Jana Borucka; Jana Petrkova; Martin Petrek
Journal:  Mediators Inflamm       Date:  2014-05-27       Impact factor: 4.711

10.  Protective effects of Acyl-coA thioesterase 1 on diabetic heart via PPARα/PGC1α signaling.

Authors:  Shenglan Yang; Chen Chen; Hong Wang; Xiaoquan Rao; Feng Wang; Quanlu Duan; Fuqiong Chen; Guangwen Long; Wei Gong; Ming-Hui Zou; Dao Wen Wang
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.